Acute lymphoblastic leukemia (ALL) in infants younger than 1 year of age is an aggressive, high-risk subtype of childhood ALL. Infant ALL with KMT2A-r is characteristically poorly responsive to chemotherapy and hematopoietic stem cell transplantation. New strategies, such as molecularly targeted therapies and immunotherapies, are in development and show promise in preclinical models and early phase studies. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• January 2022

Both fetal and tumor tissue microenvironments display immunosuppressive features characterized by the presence of specific immunomodulatory stromal and immune cell populations. Recently, we discovered shared microenvironments between hepatocellular carcinoma and fetal tissues and described this phenomenon as an oncofetal ecosystem. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• April 2023

The Opportunity The Oncogenic Signalling Laboratory is a collaborative group composed of clinical and lab-based researchers focused on the goal of ...

• 1. Telethon Kids Institute
• Be involved
• Careers and Volunteering
• Previous job vacancies

This report provides detailed characterization of carcinoma of unknown primary (CUP) in a young child and in the absence of defined therapeutic guidelines for pediatric CUP, the successful treatment strategy described should be considered for similar cases. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• May 2021

WA’s leading health agencies have joined forces to call on the State Government to immediately end junk food advertising on government property. ...

• 1. Telethon Kids Institute
• News & Events
• News & Events at Telethon Kids
• 2020
• November

PEGasparaginase is known to be a critical drug for treating pediatric acute lymphoblastic leukemia (ALL), however, there is insufficient evidence to determine the optimal dose for infants who are less than one year of age at diagnosis. This international study was conducted to identify the pharmacokinetics of PEGasparaginase in infants with newly diagnosed ALL and gather insight into the clearance and dosing of this population. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2024
• March 2024

Rishi Sury Kotecha RS MB ChB (Hons) MRCPCH FRACP PhD Co-Head, Leukaemia Translational Research rishi.kotecha@health.wa.gov.au Co-Head, Leukaemia ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• August 2022

Outcomes for infants diagnosed under 1 year of age with KMT2A-rearranged acute lymphoblastic leukemia (ALL) have remained stagnant over the past 20 years. Successive treatment protocols have previously focused on intensification of conventional chemotherapy, but increased treatment-related toxicity and chemoresistance have led to a plateau in survival. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• December 2022

The Opportunity The Brain Tumour Research Program and Oncogenic Signalling Laboratory are collaborative groups composed of clinical and lab-based ...

• 1. Telethon Kids Institute
• Be involved
• Careers and Volunteering
• Previous job vacancies

Non-communicable diseases (NCDs) such as cancer, diabetes, heart disease, mental disorder and chronic lung conditions are the leading cause of death and disability in Indonesia. Adolescence is when risks for NCDs emerge and it is also an important life stage for intervention, yet young people are often at the margins of NCD policy and actions. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• November 2023